Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

787 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Persistent mutation burden drives sustained anti-tumor immune responses.
Niknafs N, Balan A, Cherry C, Hummelink K, Monkhorst K, Shao XM, Belcaid Z, Marrone KA, Murray J, Smith KN, Levy B, Feliciano J, Hann CL, Lam V, Pardoll DM, Karchin R, Seiwert TY, Brahmer JR, Forde PM, Velculescu VE, Anagnostou V. Niknafs N, et al. Among authors: lam v. Nat Med. 2023 Feb;29(2):440-449. doi: 10.1038/s41591-022-02163-w. Epub 2023 Jan 26. Nat Med. 2023. PMID: 36702947 Free PMC article.
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancer.
Murray JC, Sivapalan L, Hummelink K, Balan A, White JR, Niknafs N, Rhymee L, Pereira G, Rao N, Phallen J, Leal A, Bartlett DL, Marrone KA, Naidoo J, Levy B, Rosner S, Hann CL, Scott SC, Feliciano J, Lam VK, Ettinger DS, Li QK, Illei PB, Monkhorst K, Zaidi AH, Scharpf RB, Brahmer JR, Velculescu VE, Forde PM, Anagnostou V. Murray JC, et al. Among authors: lam vk. bioRxiv [Preprint]. 2023 Jun 26:2023.06.23.546338. doi: 10.1101/2023.06.23.546338. bioRxiv. 2023. PMID: 37425893 Free PMC article. Updated. Preprint.
Clinical features and outcomes of advanced HER2+ esophageal/GEJ cancer with brain metastasis.
Liang K, Feliciano JL, Marrone KA, Murray JC, Hann CL, Anagnostou V, Tackett SA, Shin EJ, Hales RK, Voong KR, Battafarano RJ, Yang SC, Broderick SR, Ha JS, Forde PM, Brahmer JR, Lam VK. Liang K, et al. Among authors: lam vk. ESMO Open. 2024 Jan;9(1):102199. doi: 10.1016/j.esmoop.2023.102199. Epub 2023 Dec 9. ESMO Open. 2024. PMID: 38071928 Free PMC article.
Circulating tumor DNA and radiological tumor volume identify patients at risk for relapse with resected, early-stage non-small-cell lung cancer.
Tran HT, Heeke S, Sujit S, Vokes N, Zhang J, Aminu M, Lam VK, Vaporciyan A, Swisher SG, Godoy MCB, Cascone T, Sepesi B, Gibbons DL, Wu J, Heymach JV. Tran HT, et al. Among authors: lam vk. Ann Oncol. 2024 Feb;35(2):183-189. doi: 10.1016/j.annonc.2023.11.008. Epub 2023 Nov 21. Ann Oncol. 2024. PMID: 37992871 Free article.
First-in-human phase I study of the OX40 agonist GSK3174998 with or without pembrolizumab in patients with selected advanced solid tumors (ENGAGE-1).
Postel-Vinay S, Lam VK, Ros W, Bauer TM, Hansen AR, Cho DC, Stephen Hodi F, Schellens JHM, Litton JK, Aspeslagh S, Autio KA, Opdam FL, McKean M, Somaiah N, Champiat S, Altan M, Spreafico A, Rahma O, Paul EM, Ahlers CM, Zhou H, Struemper H, Gorman SA, Watmuff M, Yablonski KM, Yanamandra N, Chisamore MJ, Schmidt EV, Hoos A, Marabelle A, Weber JS, Heymach JV. Postel-Vinay S, et al. Among authors: lam vk. J Immunother Cancer. 2023 Mar;11(3):e005301. doi: 10.1136/jitc-2022-005301. J Immunother Cancer. 2023. PMID: 36927527 Free PMC article. Clinical Trial.
787 results